BOARD OF DIRECTORS

Upon [**REDACTED**], our Board will consist of nine Directors, comprising four executive Directors and five independent non-executive Directors. Our Directors are elected by the general meeting for a term of three years and are eligible for re-election upon expiry of their term of office. The independent non-executive Directors shall not hold office for more than six consecutive years pursuant to the relevant PRC laws and regulations.

The following table sets forth certain information of our Directors:

Name	Age	Position[1]	Time of joining our Group	Date of appointment as Director	Roles and responsibilities
Dr. Bing Yao (姚兵)	49	Executive Director and chairman of the Board	April 2019	April 7, 2023	Responsible for the overall strategic planning, business development and R&D of our Group
Mr. Long Dai (戴龍)	33	Executive Director, general manager and finance director	December 2016	May 15, 2024	Responsible for the overall operation and management, and financial and capital management of our Group
Mr. Feng Han (韓峰)	51	Executive Director	April 2006	January 25, 2017	Responsible for the operation of functional ingredients business of our Group
Ms. Wen Xu (徐雯)	36	Executive Director, employee representative Director, joint company secretary and secretary to the Board	May 2024	May 15, 2024	Responsible for Board-related matters, corporate governance, investor relations management and legal and compliance matters of our Group
Mr. Dibin Li (李迪斌)	68	Independent non-executive Director	April 2023	April 7, 2023	Responsible for supervising and providing independent opinion and judgment to the Board
Mr. Peng Yang (楊鵬)	54	Independent non-executive Director	April 2023	April 7, 2023	Responsible for supervising and providing independent opinion and judgment to the Board
Dr. Congzhi Di (邸叢枝)	50	Independent non-executive Director	April 2023	April 7, 2023	Responsible for supervising and providing independent opinion and judgment to the Board
Dr. Jianping Zhou (周建平)	65	Independent non-executive Director	May 2024	May 15, 2024	Responsible for supervising and providing independent opinion and judgment to the Board
Ms. Wang Chau (周宏)	63	Independent non-executive Director	[**REDACTED**]	[**REDACTED**]	Responsible for supervising and providing independent opinion and judgment to the Board

Note:

(1) The re-designation of the positions will take effect on the [**REDACTED**].

Executive Directors

Dr. Bing Yao (姚兵), aged 49, has been serving as our Director and chairman of the Board since April 2023 and September 2024, respectively. He joined our Group in April 2019 as a director of Megalith Biopharmaceutical and subsequently served as general manager of Megalith Biopharmaceutical from May 2020 to April 2024. He also served as the general manager of our Company from April 2024 to January 2026. Dr. Yao is primarily responsible for the overall strategic planning, business development and R&D of our Group.

Dr. Yao holds the following positions in other members of our Group: chairman of the board and director of Megalith Biopharmaceutical since November 2025 and April 2019, respectively, and director of Megalith Shanghai since October 2024.

Dr. Yao has also been serving as a director of CSPC Runshi Biotechnology (Shijiazhuang) Co., Ltd. (石藥集團潤石生物科技(石家莊)有限公司) and an executive director of CSPC Pharmaceutical since December 2025 and May 2024, respectively. Prior to that, Dr. Yao held various roles in management and R&D at CSPC Pharmaceutical from June 2016 to April 2024, including executive president, vice president, president of R&D division and assistant president. From July 2002 to June 2016, Dr. Yao worked at CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (石藥集團中諾藥業(石家莊)有限公司) ("**Zhongnuo Shijiazhuang**") and held various positions in quality and production management, with his last position as the general manager of Zhongrun production base and the deputy general manager. Concurrently, Dr. Yao was also director of the quality and procurement department of executive committee at CSPC Pharmaceutical from October 2008 to April 2009.

Dr. Yao obtained his bachelor's degree and master's degree in biochemical engineering from Nanjing Tech University (南京工業大學) in July 1999 and July 2002, respectively. He further obtained a master's degree in project management engineering from Peking University (北京大學) in January 2011 and a doctorate in chemical engineering and technology from Nanjing Tech University in December 2023.

Mr. Long Dai (戴龍), aged 33, has been our general manager since January 2026, Director since May 2024, finance director since April 2023. Mr. Dai is primarily responsible for the overall operation and management, and financial and capital management of our Group.

Mr. Dai joined our Group in December 2016 as a finance specialist and held the following positions in our Company: finance manager from December 2018 to April 2020, securities affairs representative from April 2020 to January 2026, secretary to the Board from April 2023 to January 2026 and employee representative Director from September 2025 to May 2026.

Mr. Dai has also been serving as a director of CSPC Runshi Biotechnology (Shijiazhuang) Co., Ltd. (石藥集團潤石生物科技(石家莊)有限公司) since December 2025. He also served as a finance specialist at Zhongnuo Shijiazhuang from July 2015 to December 2016.

Mr. Dai obtained his bachelor's degree in financial management from Hebei Agricultural University (河北農業大學) in June 2015.

Mr. Feng Han (韓峰), aged 51, has been serving as our Director since January 2017 and is primarily responsible for the operation of functional ingredients business of our Group.

Mr. Han joined our Group in April 2006 and successively served as our production manager, assistant to general manager, deputy general manager and general manager until April 2024. He holds the following positions in other members of our Group: director of Taizhou GWK and Megalith Biopharmaceutical (appointed in January 2018 and January 2024, respectively).

Mr. Han has also been serving as a director of CSPC Holdings Company Limited (石藥控股集團有限公司) since June 2025.

Mr. Han obtained his first bachelor's degree in pharmaceutical chemistry and his second bachelor's degree in business administration from Hebei University of Science and Technology (河北科技大學) in July 1998 and December 2006, respectively.

Ms. Wen Xu (徐雯), aged 36, has been serving as our secretary to the Board and securities affairs representative since January 2026, and our Director since May 2024. Ms. Xu has also been appointed as a joint company secretary of the Company in January 2026, and the employee representative Director since May 2026. Ms. Xu is primarily responsible for Board-related matters, corporate governance, investor relations management and legal and compliance matters of our Group.

Ms. Xu worked at CSPC Pharmaceutical as senior director of securities affairs department from October 2023 to January 2026; as medical director of clinical development department from November 2020 to October 2023; and as medical manager and associate medical director of the clinical development department from October 2018 to October 2020. Ms. Xu worked as pharmacokinetic researcher and clinical research associate at Otsuka Pharmaceutical Research and Development (Beijing) Co., Ltd. (大冢製藥研發(北京)有限公司) from July 2016 to September 2018.

Ms. Xu obtained a bachelor's degree and a master's degree in pharmacy from Zhengzhou University (鄭州大學) in July 2013 and July 2016, respectively.

Independent Non-Executive Directors

Mr. Dibin Li (李迪斌), aged 68, was appointed as our Director in April 2023 and is primarily responsible for supervising and providing independent opinion and judgment to the Board.

Mr. Li has been serving as a director of Zhongjianchuan (Beijing) Network Technology Co., Ltd. (中健傳(北京)網絡科技有限公司) since June 2022, and a director and manager of Beijing Aikang Juntai International Medical Technology Co., Ltd. (北京愛康君泰國際醫療技術有限公司) (formerly known as Beijing Aikang Juntai International Medical Technology Co., Ltd. (北京愛康君泰國際醫療技術有限公司)) since December 2015. Mr. Li also served as a producer at the news development centre of Xinhua News Agency (新華社新聞發展中心) from October 2004 to December 2014. Prior to that, he worked as a vice president of China United Advertising Corporation (中國廣告聯合總公司) from December 2001 to October 2004, and as a chief editor at Xinhua News Agency (新華通訊社) from September 1989 to December 2001.

Mr. Li obtained a bachelor's degree in Chinese language and literature from Shanxi Normal University (山西師範大學) in July 1984 and a second bachelor's degree in journalism from China Institute of Journalism (中國新聞學院) in July 1989. He has been serving as the president of the Health Communication Branch of China Health Management Association (中國健康管理協會健康傳播分會) since November 2020 and the chairperson of the Medical Communication Professional Committee of Chinese Research Hospital Association (中國研究型醫院學會醫學傳播學專業委員會) since September 2021.

Mr. Peng Yang (楊鵬), aged 54, was appointed as our Director in April 2023 and is primarily responsible for supervising and providing independent opinion and judgment to the Board.

Mr. Yang has been serving as an independent director of Mcc Meili Cloud Computing Industry Investment Co., Ltd. (中冶美利雲產業投資股份有限公司) (a company listed on the Shanghai Stock Exchange, SHSE: 000815) since May 2025, and an independent director of Zhengzhou Wote Energy-Saving Technology Co., Ltd. (鄭州沃特節能科技股份有限公司) since August 2023. He was also an independent director of Yueyang Forest & Paper Co., Ltd. (岳陽林紙股份有限公司) (a company listed on the Shanghai Stock Exchange, SHSE: 600963) from January 2022 to December 2025.

Mr. Yang has been serving as a partner of Stamina Capital Company Limited (遠驥私募基金管理(嘉興)有限公司) since August 2017. Prior to that, he served as a senior investment manager in the alternative investment division at China Re Asset Management Co., Ltd. (中再資產管理股份有限公司) from May 2013 to July 2017, and as a director of alternative investment division at China Reinsurance (Group) Corporation (中國再保險(集團)股份有限公司)(a company listed on the Stock Exchange, HKEX: 1508) from May 2011 to April 2013. From August 2003 to May 2011, Mr. Yang served as the head of the strategic development department at China Paper Investment Co., Ltd. (中國紙業投資有限公司). From June 2002 to August 2003, he served as a department manager at Fuhua building branch of Jinxin Securities Co., Ltd. (金信證券有限公司), and from August 2000 to June 2002, as a department manager at the Fuhua Building branch of Southwest Securities Co., Ltd. (西南證券股份有限公司). From July 1993 to August 2000, Mr. Yang served as the secretary of the youth league (團委書記) at Shijiazhuang Tiantong Automobile Manufacturing Co., Ltd. (石家莊天同汽車製造有限公司).

Mr. Yang obtained a bachelor's degree in mechanical and electrical engineering from Hebei University of Architecture (河北建築工程學院) in July 1993. He completed a postgraduate advanced study program in finance at Tsinghua University in September 2003 and obtained a master's degree in business administration from The Chinese University of Hong Kong in December 2003.

Dr. Congzhi Di (邸叢枝), aged 50, was appointed as our Director in April 2023 and is primarily responsible for supervising and providing independent opinion and judgment to the Board.

Dr. Di has been an independent director of Zhongyu Tiexin Transportation Technology Co., Ltd. (中裕鐵信交通科技股份有限公司) (a company listed on the National Equities Exchange and Quotations, stock code: 874484) since January 2022. She has also been working in school of accountancy at Hebei University of Economics and Business (河北經貿大學) since July 2005, serving as vice dean of the school of accountancy since July 2024, master's degree supervisor since June 2017 and associate professor since November 2015.

Dr. Di obtained a bachelor's degree in labor and human resources management from Zhongnan University of Economics and Law (中南財經政法大學) (formerly known as Zhongnan University of Finance and Economics) in June 1997, a master's degree and a doctoral degree in accounting from Renmin University of China in June 2005 and June 2011, respectively. She has been a non-practicing member of The Chinese Institute of Certified Public Accountants ("**CICPA**") (中國註冊會計師協會) since August 2005.

Dr. Di was also recognized as a High-level Accounting Talent under the Ministry of Finance's Accounting Talent Quality Enhancement Project (財政部高層次財會人才素質提升工程人才) in November 2023, a High-end Accounting Talent of Hebei Province (河北省高端會計人才) in September 2023, special task force expert for the International Federation of Accountants and Confederation of Asian and Pacific Accountants Council Councils under CICPA in September 2023, government procurement review expert for the Hebei Provincial Government in September 2022 and an Expert in the Hebei Provincial Finance Professional Experts' Database (河北省省級財政專業人才庫專家) in December 2020.

Dr. Jianping Zhou (周建平), aged 65, was appointed as our Director in May 2024 and is primarily responsible for supervising and providing independent opinion and judgment to the Board.

Dr. Zhou has been serving as a director of Nanjing Haina Medical Technology Co., Ltd. (南京海納醫藥科技股份有限公司) since March 2023, director of Suzhou Teligenne Ltd. (蘇州韜略生物科技股份有限公司) since October 2021, and independent director of Anhui Sunhere Pharmaceutical Excipients Co., Ltd. (安徽山河藥用輔料股份有限公司) (a company listed on the ChiNext Market of the Shenzhen Stock Exchange, SZSE: 300452) since July 2020. He was also an independent director of Jiangsu Deyuan Pharmaceutical Co., Ltd. (江蘇德源藥業股份有限公司) (a company listed on the Beijing Stock Exchange, BSE: 920735) from December 2020 to October 2025.

Dr. Zhou has been working in school of pharmacy at China Pharmaceutical University (中國藥科大學) since August 1988, serving as a director of pharmaceutics teaching and research division since March 2006, a doctoral supervisor since June 2002, a professor since April 2001, and an associate professor from April 1993 to March 2001.

Dr. Zhou currently serves as a professor and doctoral supervisor of the school of pharmacy at China Pharmaceutical University (中國藥科大學). Dr. Zhou obtained a doctoral degree in pharmaceutics from China Pharmaceutical University (formerly known as Nanjing Pharmaceutical College) in June 2002. He is also an executive member of the State Pharmacopoeia Commission (國家藥典委員會) and an executive council member of the pharmaceutics committee of the Jiangsu Pharmaceutical Association (江蘇省藥學會). Dr. Zhou was awarded the Jiangsu provincial science and technology award in March 2019 and the title of expert entitled to special allowance from the State Council.

Ms. Wang Chau (周宏), aged 63, was appointed as our independent non-executive Director with effect from the [**REDACTED**] and she will be primarily responsible for supervising and providing independent opinion and judgment to the Board.

Ms. Chau has been serving as an executive director of Right Lane Limited (南明有限公司) ("**Right Lane**"), a subsidiary of Legend Holdings Corporation (聯想控股股份有限公司) ("**Legend Holdings**") (HKEX: 3396) since August 2017, responsible for the overall business management and operation of Right Lane. Prior to that, she was general manager of Right Lane from 2006, in which role she oversaw various matters of Right Lane including finance, project execution and risk and internal control. From October 1994 to March 2006, Ms. Chau worked as a secretary to the chairman of the board at Legend Holdings.

Ms. Chau graduated from Kunming Railway Vocational and Technical College (昆明鐵道職業技術學院) with a major in English in July 1981.

SENIOR MANAGEMENT

In addition to our Directors, our senior management is responsible for the day-to-day management of our business. The table below sets forth certain information of each of our members of senior management:

Name	Age	Position	Time of joining our Group	Date of appointment as senior management	Roles and responsibilities
Mr. Long Dai (戴龍)	33	Executive Director, general manager and finance director	December 2016	April 7, 2023	Responsible for the overall operation and management, and financial and capital management of our Group
Ms. Wen Xu (徐雯)	36	Executive Director, joint company secretary and secretary to the Board	May 2024	January 29, 2026	Responsible for Board-related matters, corporate governance, investor relations management and legal and compliance matters of our Group
Dr. Xiwu Hui (惠希武) . . .	41	Deputy general manager	April 2020	March 19, 2025	Responsible for the overall R&D of our Group

Mr. Long Dai (戴龍), aged 33, is our executive Director, general manager and finance director. For the biographical details of Mr. Dai, please refer to "—Board of Directors—Executive Directors" in this section.

Ms. Wen Xu (徐雯), aged 36, is our executive Director, joint company secretary and secretary to the Board. For the biographical details of Ms. Xu, please refer to "—Board of Directors—Executive Directors" in this section.

Dr. Xiwu Hui (惠希武), aged 41, has been serving as our deputy general manager since March 2025 and is primarily responsible for the overall R&D of our Group.

Dr. Hui has been serving as the head of research institute of Megalith Biopharmaceutical since April 2024. He joined Megalith Biopharmaceutical in April 2020, successively served as senior researcher, chief researcher, deputy general manager and deputy head of research institute until April 2024. He was also a director of Megalith Biopharmaceutical from February 2025 to November 2025.

Dr. Hui was appointed as a director of Wuhan YZY Biopharma Co., Ltd. (武漢友芝友生物製藥股份有限公司) (HKEX: 2496) in September 2022 and has been serving as its non-executive director since November 2022. He served at CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (石藥集團中奇製藥技術(石家莊)有限公司) as a senior researcher from April 2020 to February 2021, deputy head and head of the third institute of the central pharmaceutical research institute (中央藥物研究院三院) from October 2018 to April 2020 and R&D engineer of biotechnology research institute from July 2012 to October 2018.

Dr. Hui obtained a bachelor's degree in bioscience from Yantai University (煙台大學) in June 2006. He further obtained his master's degree and doctorate degree in biochemistry and molecular biology through the successive postgraduate and doctoral program from Peking Union Medical College (北京協和醫學院) in July 2012.

GENERAL

Save as disclosed in this section, none of our Directors or members of the senior management is related to other Directors or members of senior management of our Company. Save as disclosed in this section, (i) none of our Directors or senior management members held any directorships in public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years immediately preceding the Latest Practicable Date; and (ii) to the best knowledge, information and belief of the Directors and having made all reasonable inquiries, there were no other matters with respect to the appointment of the Directors that need to be brought to the attention of the Shareholders and there was no information relating to our Directors that is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

JOINT COMPANY SECRETARIES

Ms. Wen Xu (徐雯) is one of our joint company secretaries. For the biographical details of Ms. Xu, please refer to "—Board of Directors—Executive Directors" in this section.

Ms. Ka Man Lee (李嘉文) is one of our joint company secretaries. Ms. Lee is an associate member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom. She has over 20 years of experience in the field of company secretarial services and is currently a senior manager of Fair Wind Secretarial Services Limited, a company rendering company secretarial services. Ms. Lee has been and is currently serving as company secretary of a number of companies listed on the Stock Exchange.

CONFIRMATION FROM OUR DIRECTORS

Rule 3.09D of the Listing Rules

Each of our Directors confirms that he or she (i) has obtained the legal advice referred to under Rule 3.09D of the Listing Rules in November 2025, and (ii) understands his or her obligations as a director of a [**REDACTED**] under the Listing Rules.

Rule 3.13 of the Listing Rules

Each of the independent non-executive Directors has confirmed (i) his or her independence as regards each of the factors referred to in Rules 3.13(1) to (8) of the [**REDACTED**] Rules, (ii) he or she has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person of the Company under the [**REDACTED**] Rules as of the Latest Practicable Date, and (iii) that there are no other factors that may affect his or her independence at the time of his or her appointments.

DISCLOSURE UNDER RULE 8.10(2) OF THE LISTING RULES

As of the Latest Practicable Date, none of our Directors has an interest in any business which competes or is likely to compete (either directly or indirectly) with our business and which is required to be disclosed under Rule 8.10(2) of the Listig Rules.

BOARD COMMITTEES

We have established four Board Committees in accordance with the relevant laws and regulations in Chinese Mainland, the Articles and the code of corporate governance practices under the Listing Rules, namely the Audit Committee, the Remuneration and Evaluation Committee, the Nomination Committee and the Strategy and ESG Committee. The functions of the four committees are summarized as follows:

Audit Committee

We have established the Audit Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The Audit Committee consists of Dr. Congzhi Di (being the independent non-executive director who holds the appropriate professional qualifications as required under Rules 3.10(2) and 3.21 of the Listing Rules), Mr. Peng Yang and Dr. Jianping Zhou. The chairperson of the Audit Committee is Dr. Congzhi Di.

The primary duties of the Audit Committee are to, among others, consider issues in relation to the external auditors and their appointment, oversee the financial reporting system, risk management and internal control systems of our Group, review the financial information of our Group and review policies and practices in relation to corporate governance.

Remuneration and Evaluation Committee

We have established the Remuneration and Evaluation Committee with written terms of reference in compliance with Rule 3.25 of the Listing Rules and the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The Remuneration and Evaluation Committee consists of Mr. Dibin Li, Dr. Congzhi Di and Mr. Long Dai. The chairperson of the Remuneration and Evaluation Committee is Mr. Dibin Li.

The primary duties of the Remuneration and Evaluation Committee are to, among others, review the remuneration policy and make recommendations to our Board on the remuneration packages of our Directors and other senior management.

Nomination Committee

We have established the Nomination Committee with written terms of reference in compliance with Rule 3.27A of the Listing Rules and the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The Nomination Committee consists of Mr. Peng Yang, Dr. Congzhi Di and Dr. Bing Yao. The chairperson of the Nomination Committee is Mr. Peng Yang.

The primary duties of the Nomination Committee are to, among others, assess and make recommendations on appropriate candidates for directorship, propose procedures and criteria for the appointment of Directors, review the structure, size and composition of our Board, and assess the independence of independent non-executive Directors.

Strategy and ESG Committee

We have established the Strategy and ESG Committee with written terms of reference. The primary duties of the Strategy and ESG Committee are to, among others, conduct research and make recommendations to our Board on the long-term development strategy and major investment decisions of our Company, conduct research and provide recommendations in respect of our Company's ESG objectives, governance framework and management policies, identify and assess ESG-related risks facing our Company, and review our Company's ESG report and relevant disclosures.

The Strategy and ESG Committee consists of Dr. Bing Yao, Mr. Feng Han and Mr. Dibin Li. The chairperson of the Strategy and ESG Committee is Dr. Bing Yao.

CORPORATE GOVERNANCE CODE

We aim to achieve high standards of corporate governance which are crucial to our development and safeguard the interests of our Shareholders. Our Directors recognize the importance of incorporating elements of good corporate governance in the management structures and internal control procedures of our Group to achieve effective accountability. We intend to comply with the Corporate Governance Code set out in Appendix C1 to the Listing Rules after the [**REDACTED**].

Board Diversity Policy

We [have] adopted a diversity policy (the "**Board Diversity Policy**") which sets out the objective and approach to achieve and maintain diversity in our Board in order to enhance the effectiveness of our Board. Pursuant to the Board Diversity Policy, we seek to achieve diversity in our Board through the consideration of a number of factors when selecting candidates to our Board, including but not limited to skills, regional and industry experience, professional experience, cultural and educational background, gender and age, ethnicity and length of service.

Our Directors have a balanced mix of knowledge and skills including in biochemical engineering, pharmacy, pharmaceutics and accounting and financial management, and we have seven non-executive Directors, including five independent non-executive Directors, with different industry and management backgrounds.

Besides, we particularly recognize the importance of gender diversity, which is an essential element in maintaining our Company's competitive advantage and enhancing our ability to attract, retain and motivate employees from the widest possible pool of available talent. Our Company currently has three female Directors on the Board. Going forward, we will continue to work to enhance gender diversity of our Board when selecting and recommending suitable candidates for Board appointments. Taking into account our existing business model and specific needs as well as the different backgrounds of our Directors, the composition of our Board satisfies our Board Diversity Policy.

Our Nomination Committee is responsible for ensuring the diversity of our Board members. After [**REDACTED**], our Board will monitor the implementation of the Board Diversity Policy and review the Board Diversity Policy from time to time to ensure its effectiveness. We will also disclose in our annual corporate governance report a summary of the Board Diversity Policy together with information regarding the implementation of the Board Diversity Policy.

Management Presence

Pursuant to Rule 8.12 of the Listing Rules, an issuer must have a sufficient management presence in Hong Kong. This will normally mean that at least two of its executive directors must be ordinarily resident in Hong Kong. We do not have sufficient management presence in Hong Kong for the purposes of Rule 8.12 of the Listing Rules.

We have applied for, and the Stock Exchange [has granted], a waiver from compliance with Rule 8.12 of the Listing Rules. For further details, see "Waivers and Exemption—Management Presence in Hong Kong."

REMUNERATION

Our Directors and senior management receive their remuneration in the form of salaries, wages and other benefits, performance related bonuses and contribution to retirement benefit schemes subject to applicable laws, rules and regulations. For details of the service contracts and appointment letters that we have entered into with our Directors, see the section headed "C. Further Information About Our Directors and Substantial Shareholders—2. Particulars of Service Contracts and Appointment Letters" in Appendix VI to this document.

Further information on the remuneration of our Directors and/or the five highest paid individuals during the Track Record Period is set out in the Accountants' Report in Appendix I to this document, and in the section headed "C. Further Information About Our Directors and Substantial Shareholders—3. Directors' Remuneration" in Appendix VI to this document. Save as disclosed, the Directors are not entitled to receive any other special benefits from our Company. The compensation of the Directors is determined by the Board which, following [**REDACTED**], will receive recommendations from the Remuneration and Evaluation Committee which will take into account applicable laws, rules and regulations.

COMPLIANCE ADVISER

We have appointed Altus Capital Limited as our compliance adviser (the "**Compliance Adviser**") upon [**REDACTED**] in compliance with Rule 3A.19 of the Listing Rules. The compliance adviser will provide us with guidance and advice as to compliance with the requirements under the Listing Rules and applicable Hong Kong laws. Pursuant to Rule 3A.23 of the Listing Rules, the compliance adviser will advise our Company, among others, in the following circumstances:

(a) before the publication of any regulatory announcement, circular, or financial report;

(b) where a transaction, which might be a notifiable or connected transaction, is contemplated, including share issues, sales or transfers of treasury shares and share repurchases;

(c) where we propose to use the [**REDACTED**] in a manner different from that detailed in this document or where the business activities, development or results of our Group deviate from any forecast, estimate or other information in this document; and

(d) where the Hong Kong Stock Exchange makes an inquiry to our Company under Rule 13.10 of the Listing Rules.

The term of appointment of the compliance adviser shall commence on the [**REDACTED**] and is expected to end on the date on which we comply with Rule 13.46 of the Listing Rules in respect of our financial results for the first full financial year commencing after the [**REDACTED**] and such appointment may be subject to extension by mutual agreement.